A patient-level pooled analysis combining the DEBBRAH and TUXEDO-1 trials along with the DFCI/Duke/MDACC cohort, published in ESMO Open (January 3, 2025), demonstrated clinically meaningful intracranial efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive breast cancer and active brain metastases.
Despite heavy prior treatment, the study reported an intracranial objective response rate of 64.9% and a clinical benefit rate of 81.1%, with a median progression-free survival of 13.3 months and median overall survival of 22.5 months. These results reinforce T-DXd as a viable option even for patients with previously untreated or progressing brain metastases.
This important work reflects the collective efforts of an international team of investigators across multiple institutions. Their collaboration provides meaningful real-world insights into managing HER2-positive breast cancer with CNS involvement.
For more details, see the full article here: https://lnkd.in/eAJTEeHY
